哪里想瘦打哪里！FDA首肯Kythera注射药物上市在即

你才双下巴，你全家都双下巴！所谓爱美之心人皆有之。如果说赘肉是每一个想要占有完美身材的“妹纸”或“汉纸”的大敌，那么一个喜感十足的双下巴可谓是这些人的命运罪人了。每一分钟，为数众多都有人为自己的一张大饼脸而极度烦恼，虽然占有一个肉感十足的双下巴捏上去是挺有肉感的，但是还是有很多人的心理素质使其无法背负一个双下巴之重。您可千万别笑，这甚至已经转变成一个相当可观的市场。根据新泽西州皮肤外科手术协可能会的追查研究显示，68%的新泽西州人对自己的双下巴说明了“不感兴趣”之情。而有鉴于此，最近KytheraCorporation向FDA送交了其专门消灭双下巴的化妆麻醉型式制剂ATX-101。这种制剂完成了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，可谓是定点肥胖。不要以为这种却是任性的制剂只是一个玩笑，在FDA下属的皮肤和儿科制剂专员可能会的无记名投票中可能会，专家可是以17：0的超高票数一致采纳其香港交易所。确实是因为这些专家中可能会也有很多不堪双下巴之苦吧。FDA也将计划于本年度的5月13日之前对其重新考虑最后尽快。如果一切顺利的话，KytheraCorporation计划于本年度下半年将该产品香港交易所，分析香港市民原定这一制剂的沃尔玛将至少3亿美元之多。随着化妆制剂市场的日益增大，KytheraCorporation可谓是下了一步好棋。Corporation于去年以8400万美元的价格从其前合作伙伴伙伴穆勒据为己有可能会收回了这种制剂的全部公民权。而KytheraCorporation也想要以此为后所在化妆制剂市场中可能会火攻拔寨。就在上个月，KytheraCorporation和ActelionCorporation进行谈判意义2700万美元的合作伙伴协定，共同开发一种惨败过的抗炎症制剂，而这种制剂被认为有可能开发出一种治疗脱发的制剂。概要英文美联社：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.